First Quarter Revenue Increased 14% to $156 Million NeoGenomics, Inc. (NASDAQ: NEO) (the “Company”), a leading provider of oncology testing and...
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced two promotions within its senior leadership team...
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced that it will report its first quarter 2024...
Insights from 11 Abstracts Highlight Key Findings Across the Oncology Care Spectrum NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing...
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today released its 2023 Environmental, Social, and Governance (ESG...
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced the company will participate in the upcoming TD...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.